lung cancer
Conditions
Interventions
A blood draw is performed once from the time of planning the definitive diagnosis of lung cancer to before the start of chemotherapy, which is equivalent to first-line treatment. Blood samples will be
s visit to the hospital or incidental to the blood collection at the time of admission, and two blood collection tubes (approximately 14 ml) will be collected as needed. If consent is obtained for blo
Sponsors
Cancer Institute Hospital of Japan Foundation for Cancer Research
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Cases in which advanced stage lung cancer is suspected and pathological diagnosis is being considered. 2) Cases in which curative treatment is not available and are expected to be treated with systemic treatment. 3) No prior systemic treatment. (Cases of recurrence after adjuvant chemotherapy or radical chemoradiotherapy that are considered prior to the first systemic treatment are acceptable. 4) Age: 18 years and older 5) Any PS (Performance status) is permitted. 6) Measurable lesions are not required.
Exclusion criteria
Exclusion criteria: non
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The concordance rate of gene subtypes diagnosis between based on pathology diagnosis and on plasma analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Efficacy of molecular targeted therapy (response rate, progression-free survival) 2. Detection rate of driver genes by plasma analysis 3. Rate of confirmed gene subtypes by plasma analysis in cases in which driver gene analysis was not possible | — |
Countries
Japan
Contacts
Public ContactKen Uchibori
Cancer Institute Hospital of Japan Foundation for Cancer Research The Division of Thoracic Medical Oncology
Outcome results
None listed